MEDECIELO MELO - Chapter 8 Summary
MEDECIELO MELO - Chapter 8 Summary
MEDECIELO MELO - Chapter 8 Summary
Medecielo
Chapter Title: EvidenceBased Clinical Practice Guidelines
Self-Assessment questions
Copy + Paste the Self-Assessment questions. Provide your answer and rationale with
citations. Follow the sample given below.
Answer:
Choice: A
Rationale:
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 5
3. Clinical practice guidelines are essential to getting research findings into practice
because:
a. Wellstudied new treatments proven effective are substantially underutilized.
b. Interventions found to be ineffective or harmful continue to be provided.
c. Research information is not readily available for implementation into practice.
d. a and b only are essential.
e. b and c only are important.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 3
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 2
5. Which of the following is among the five core competencies for health professionals as
recommended in a landmark Institute of Medicine report?
a. Deliver patientcentered care.
b. Participate in interdisciplinary teams.
c. Utilize informatics.
d. All of the above.
6. The first step in the Institute of Medicine’s proposed standards for developing
evidencebased clinical practice guidelines is:
a. Conduct a systematic review for qualifying evidence.
b. Establish an interdisciplinary guideline development group.
c. Establish transparency.
d. Manage conflict of interest.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 3
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 6
8. Which of the following characteristics associated with a disease would suggest that it
would be a good topic for the development and
implementation of a practice guideline?
a. Evidence that current practice is optimal
b. Evidence of little variation in current practice
c. Availability of highquality evidence for the efficacy of treatments that reduce morbidity or
mortality
d. Low frequency and/or severity of morbidity or mortality
Answer: Availability of high quality evidence for the efficacy of treatments that reduce
morbidity or mortality
Choice: C
Rationale: Characteristics of disease states with the maximum potential to benefit from
guidelines includes availability of high qualityfor the efficacy of treatments that reduce morb.
And mortality.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 9
Answer: comparison
Choice: B
Rationale: comparison means what other interventions or treatments were compared with
the interventions considered.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 9
10. When using the GRADE system, which of the following information should be
incorporated with guideline recommendations?
a. Quality of evidence across studies for each critical outcome
b. Strength of the recommendations
c. The balance between benefits and harms
d. a and b only
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 11
11. When using the GRADE system, all of the following are reasons for lowering the level of
confidence rating except:
a. Publication bias
b. Imprecision
c. Indirectness
d. Consistency
Answer: consistency
Choice: D
Rationale: the rating are increased or decreased based on five reasons which are risk of
bias, inconsistency , indirectness, imprecision and publication bias.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 12
12. When using the GRADE system, which of the following is a reason for rating the level of
confidence higher?
a. Doseresponse relationship
b. Large effect size
c. b and c only
d. a, b, and c
Answer: A, B and C
Choice: D
Rationale: the level of confidence similarly can be increased based on three reasons; large
effect size, dose response and all plausible confounding.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 12
13. All of the following are true regarding the AGREE II instrument for guideline evaluation
except:
a. Created by an international group of researchers and policymakers
b. Provides a framework to assess the quality of guidelines
c. Assesses the quality of the clinical content
d. Provides a methodological strategy for the development of guidelines
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 16
14. External barriers to clinical practice guideline implementation include all of the following
except:
a. Cost to patient
b. Increased malpractice liability
c. Insufficient staff, consultant support, or other resources
d. Lack of reimbursement
Answer: NOTA
Choice: None
Rationale: All of the following are part of the External Barriers
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 20
15. All of the following statements about clinical practice guidelines are true except:
a. Clinical practice guidelines should contain all necessary elements of routine care for
most individuals with a specific condition.
b. Clinical practice guidelines should not prompt consideration of the specific characteristics
of an individual patient that might warrant departures from the guideline.
c. Clinical practice guidelines represent an application of decision support systems to
facilitate providing quality clinical care.
d. Clinical practice guidelines should be part of the continuous improvement of systems of
care.
Reference: Abrons, J., & Kukreja, P. (2023). Drug Information: A Guide for Pharmacists. 23